Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.

Ongoren, Seniz; Eskazan, Ahmet; Suzan, Veysel; Savci, Sercan; Ozunal, Isil; Berk, Selin; Yalniz, Fevzi; Elverdi, Tuğrul; Salihoglu, Ayse; Erbilgin, Yücel; Iseri, Sibel; Ar, Muhlis; Baslar, Zafer; Aydin, Yildiz; Tuzuner, Nukhet; Ozbek, Ugur; Soysal, Teoman

doi:10.1080/10245332.2017.1385193

Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.

Copy For Citation

Ongoren S., Eskazan A. E., Suzan V., Savci S., Ozunal I. E., Berk S., ...More

Hematology (Amsterdam, Netherlands), vol.23, no.4, pp.212-220, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 23 Issue: 4
Publication Date: 2018
Doi Number: 10.1080/10245332.2017.1385193
Journal Name: Hematology (Amsterdam, Netherlands)
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.212-220
Istanbul University Affiliated: Yes

Abstract

Objectives: Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib -> nilotinib or imatinib -> dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all patients can undergo allo-HSCT.